RecruitingNot ApplicableNCT04554277

Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure

Sponsor

University Hospital, Montpellier

Enrollment

710 participants

Start Date

Apr 27, 2021

Study Type

INTERVENTIONAL

Conditions

Heart Failure

Summary

Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. As a working hypothesis, we postulate that sST2 values monitoring could be an helpful guide for medical management in an attempt to reduce hospital readmission.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a blood biomarker called sST-2 can help doctors better manage treatment for patients hospitalized with acute heart failure, potentially improving outcomes while reducing healthcare costs. **You may be eligible if...** - You are 18 years or older - You are being hospitalized for heart failure with elevated heart failure markers in your blood **You may NOT be eligible if...** - You are waiting for a heart transplant - You are scheduled for valve surgery - You do not speak fluent French - You are unable to give consent - Your condition is unstable - Your recovery in the first week has been poor - You are pregnant - You are currently participating in another clinical study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBiomarker guided therapy

Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.

Locations(12)

Lapeyronie Hospital

Montpellier, Occitanie, France

CHU Angers

Angers, France

CHU Besançon

Besançon, France

CH Béziers

Béziers, France

CHU Caen

Caen, France

CHU Grenoble

Grenoble, France

Arnaud de Villeneuve Hospital

Montpellier, France

CHU Nimes

Nîmes, France

APHP Pompidou

Paris, France

CHU Rennes

Rennes, France

CHU Toulouse

Toulouse, France

CHU Vannes

Vannes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04554277

Related Trials

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370638 locations

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288653 locations

Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker

NCT075631531 location

HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management

NCT074022391 location

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257135 locations